Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022)

The findings of this study indicate that the most effective way to reduce NPS availability in the UK is via legislation in producer countries, as evidenced by substantial declines in their detections in deaths following their control in China. This reliance on international controls places the UK in a vulnerable position, as its domestic drug landscape is being shaped largely by the pace and scope of independent international legislations. To achieve and maximise effectiveness, UK drug policy needs to integrate harm reduction measures alongside the introduction of legislative controls, whilst also encouraging international efforts to bring in global control of problem materials.